Browsing Category
Pharma Industry News
4139 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Could SBS-147 become a credible challenger to opioid-based pain management pathways?
Could SBS-147 challenge opioid-based pain treatment pathways? Read how Sparian Biosciences’ Phase 1 launch could reshape the non-opioid market.
Could MTX-001 emerge as a late-stage wound care contender after the latest FDA alignment?
Could MTX-001 emerge as a late-stage wound care contender? Read why Merakris Therapeutics’ latest FDA alignment may reshape the commercial outlook.
How the gammaCore PTSD study may influence bioelectronic medicine adoption in mental health
Can gammaCore’s PTSD study accelerate bioelectronic medicine adoption in mental health? Read what this means for electroCore, Inc. and the sector.
How the Japan patent allowance could strengthen RenovoRx’s oncology platform valuation story
Could RenovoRx’s Japan patent strengthen the RNXT valuation story? Read what this means for growth, competition, and investor sentiment.
Why pediatric ependymoma inclusion may be the bigger strategic signal for Plus Therapeutics
Why pediatric ependymoma may be the bigger strategic signal for Plus Therapeutics and what it means for REYOBIQ’s 2026 growth roadmap. Read more.
Why Wall Street and clinicians may be watching IKT-001 more closely after the Phase 3 launch
Could IKT-001 change the PAH treatment landscape? Read why Inhibikase Therapeutics’ Phase 3 launch could become a major 2026 biotech catalyst.
Replimune Group (NASDAQ: REPL) plans layoffs after FDA rejects Tudriqev again, forcing a biotech reset
Replimune plans layoffs after the FDA rejected Tudriqev again. Read what the setback means for REPL stock, cash runway, strategy, and rivals.
Why Seaport’s U.S. IPO filing matters now for neuropsychiatric drug development and biotech capital markets
Seaport Therapeutics has filed for a U.S. IPO. Read how its neuropsychiatry pipeline could test biotech investor appetite in 2026.
Why Abbott Laboratories (NYSE: ABT) faces more than a legal bill after $70m Chicago baby formula ruling
Abbott was ordered to pay $70 million in a Chicago baby formula case. Read what the NEC verdict could mean for litigation risk, strategy, and ABT stock.
ASCRS 2026 in Washington DC: What ophthalmologists need to know
ASCRS 2026 annual meeting runs April 10-13 in Washington DC. Full guide to the programme, key speakers, technology announcements, SightLine, and CME for anterior segment surgeons.